Medabon, a quality assured mifepristone-misprostol combipack has been registered in Kyrgyzstan.
Concept Foundation is pleased to announce that over the coming year it will be working to address maternal health supply gaps in Ethiopia, with a new grant from the RHSC Innovation Fund.
At the end of last month, the WHO announced the implementation of a new financing model for their Prequalification programme, to take effect in January 2017. The detailed scheme and other questions and answers that any manufacturers may have are also available on the WHO website.
Inresa Arzneimittel GmbH have achieved WHO prequalification on 15 August 2016 for their magnesium sulfate heptahydrate (MgSO4) 500 mg/ml injection with technical assistance from Concept Foundation. This is the first such product to be prequalified.
On the same day, China Resources Zizhu have had their mifepristone 200mg product added to the list of WHO prequalified medicines for use in combination with misoprostol, as have Jai Pharma Ltd with their levonorgestrel 0.03mg progestin-only contraceptive.
On 15 July 2016, the committee for the National Essential Drugs (NED) list in Thailand included Medabon® to the NED list.